ClinicalTrials.gg
CompletedNCT03268512Updated Oct 11, 2018

Effect of L-PRF and A-PRF in Ridge Preservation

An interventional study of L-PRF and A-PRF in Atrophic Maxilla and Ridge Preservation, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Aug 2015, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A split-mouth design study will be performed regarding the use of platelet concentrates on ridge preservation: L-PRF vs A-PRF vs control. Patient needing multiple teeth extractions in the upper jaw (single-rooted teeth) will be recruited. The use of each platelet concentrate or control will be randomized by means of a computer program. The results will be analysed clinical and radiographically (CBCT). When the subject will choose for implant rehabilitation, a biopsy will be taken in the site of the preserved sockets. The region will be localized with a customized stent, fabricated with the position of the extracted teeth. VAS scales will be provided to evaluate the post-operative discomfort.

02

Conditions studied

  • Atrophic Maxilla
  • Ridge Preservation

Browse trials for

Keywords

  • leucocyte- and platelet rich fibrin
  • ridge preservation
  • growth factors
  • platelet concentrates
03

In context

Atrophic Maxilla

30 studies on the registry are indexed under Atrophic Maxilla; 11 are open to participants now.

This study's enrollment of 20 is above the median of 16 across 27 interventional studies indexed under Atrophic Maxilla.

Browse Atrophic Maxilla studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3 single-rooted teeth needed to be extracted in the upper jaw
  • patient in good general health as documented by self-assessment
  • patients must be committed to the study and must be willing to sing the .

Exclusion criteria

Exclusion Criteria:

  • any systemic medical condition that could interfere with the surgical procedure or planned treatment.
  • current pregnancy or breast feeding
  • radiotherapy or chemotherapy in head and neck area
  • intravenous and oral bisphosphonate
  • patients smoking >20 cig/day
  • unwillingness to return for the follow-up examination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    L-PRF

    One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.

    Other: L-PRF

  • Experimental
    A-PRF

    One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.

    Other: A-PRF

  • No intervention
    Control

    The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.

Interventions

  • OtherL-PRF

    Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called "buffy coat" where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.

  • OtherA-PRF

    Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called "buffy coat" where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.

06

What researchers measure

Primary outcomes

  1. Changes horizontal width at crest -1mm

    Primary outcome variables were defined as the changes in horizontal width at crest-1 mm levels.

    Time frame: 3 months

Secondary outcomes

  1. Changes horizontal width at crest -3 mm and 5 mm; vertical resorption; socket fill

    Changes in horizontal width at crest -3 mm and 5 mm; vertical resorption at the lingual and buccal side; socket fill.

    Time frame: 3 months

Other outcomes

  1. Post-operative scores

    Post-operative discomfort measured with VAS

    Time frame: 1 week

07

Study locations

1 site
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03268512
Responsible party
Ana CASTRO SARDA (Doctoral researcher, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Aug 31, 2017
Start date
Aug 22, 2015
Primary completion
Oct 10, 2018
Completion
Oct 10, 2018
Last update
Oct 11, 2018

Study contacts

Ana B Castro, PhD student
principal investigator · UZ Leuven

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion